| HOME >> BIOLOGY >> TECHNOLOGY |
7,669$
26,981$
28,182Commercial revenues1,4509404,3323,372Total revenues8,1848,60931,31331,554Operating expenses:Cost of commercial revenues10066303219Research and development (including $514, $452, $1,876 and $2,129, respectively, of non-cash stock-based compensation)7,1867,05828,64428,687General and administrative (including $662, $682, $2,594 and $2,678, respectively, of non-cash stock-based compensation)3,1213,17111,61911,500Total operating expenses10,40710,29540,56640,406Loss from operations(2,223)(1,686)(9,253)(8,852)Other income102967128Net loss$
(2,213)$
(1,657)$
(9,186)$
(8,724)Basic and diluted net loss per share$
(0.06)$
(0.04)$
(0.23)$
(0.22)Weighted average shares used in computing basic and diluted net loss per share40,10039,75239,95639,571
Condensed Balance Sheets(in thousands) December 31,
2012December 31,
2011(unaudited)Cash, cash equivalents and investments available-for-sale$
41,823$
55,106Other current assets3,5473,140Property and equipment, net7,9109,400Total assets$
53,280$
67,646Accounts payable, accrued expenses and other current liabilities$
6,538$
6,117Deferred revenues15,58025,282Deferred rent1,3211,426Leasehold incentive obligation4,1135,100Stockholders' equity25,72829,721Total liabilities and stockholders' equity$
53,280$
67,646
'/>"/>
| SOURCE Senomyx Copyright©2012 PR Newswire. All rights reserved |